Skip to main content

Table 3 Prognostic/predictive factors at univariate analysis

From: Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

Predictive for survival N HR 95% CI Median survival (months) 2-sided P value
AREG mRNA (25th percentile)   0.47 0.31-0.70   0.0002
High 124    29  
Low 40    16  
EREG mRNA (75th percentile)   0.45 0.28-0.72   0.0009
High 39    36  
Low 117    23  
BRAF   8.1 3.44-19.0   0.00005
Mutation 6    12  
Wild type 208    28  
KRAS codon 12   1.62 1.10-2.38   0.014
Mutation 44    19  
Wild type 129    29  
Predictive for Response   Odds Ratio for Response 95% CI   2-sided P
AREG mRNA at 25th percentile   1.59 0.67-3.77   0.29
High vs. Low      
EREG mRNA at 75th percentile   2.26 1.04-4.91   0.04
High vs. Low